Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT

Current Pathobiology Reports

Volumn 2, Issue 1, 2014, Pages 21-26

  Abell, Amy N ^a   Johnson, Gary L ^b  

^a UNIVERSITY OF MEMPHIS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells (CSCs); Cell plasticity; Circulating tumor cells (CTCs); EMT; Epigenetics

Indexed keywords

EID: 84942426976     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-013-0034-7     Document Type: Article

References (26)

1. Kalluri R, Weinberg RA (2009) The basics of epithelial–mesenchymal transition. J Clin Investig 119:1420–1428
2. Zeisberg M, Neilson EG (2009) Biomarkers for epithelial–mesenchymal transitions. J Clin Investig 119:1429–1437
3. Hay ED (2005) The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it developmental dynamics. Dev Dyn 233:706–720
4. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial–mesenchymal transitions in development and disease. Cell 139:871–890
5. Visvader JE, Lindeman GJ (2012) Cancer stem cells: current status and evolving complexities. Cell Stem Cell 10:717–728
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
7. Radisky DC, LaBarge MA (2008) Epithelial–mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2:511–512
8. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106:13820–13825
9. ∙ Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361. One of the few in vivo demonstrations of metastasis showing pancreatic cancer cells with features of EMT and stemness. Some of these cancer stem cell like cells were in an “intermediate EMT”, simultaneously expressing both epithelial and mesenchymal markers
10. Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL (2011) MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell 8:525–537
11. Jordan NV, Johnson GL, Abell AN (2011) Tracking the intermediate stages of epithelial–mesenchymal transition in epithelial stem cells and cancer. Cell Cycle 10:2865–2873
12. Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL (2013) SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial–mesenchymal transition by inducing Wnt5a signaling. Mol Cell Biol 33:3011–3025
13. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP (2013) MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154:311–324
14. Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, Herschkowitz JI, Rosen JM, Issa JP, Calin GA, Chang JT, Mani SA (2013) Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep 3:2687
15. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468–476
16. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, Kah KJ, Bell G, Guo W, Rubin J, Richardson AL, Weinberg RA (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145:926–940
17. ∙ Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. In Proceedings of the national academy of sciences of the United States of America, vol 108, pp. 7950–7955. Demonstration of the plasticity of non-CSCs to become CSCs. This dedifferentiation is dependent on both signals from the microenvironment and the configuration of the ZEB1 promoter
18. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA (2011) Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 9:997–1007
19. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial–mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11:R46
20. Barriere G, Riouallon A, Renaudie J, Tartary M, Rigaud M (2012) Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer 12:114
21. Barriere G, Tartary M, Rigaud M (2012) Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol 2012:382010
22. ∙ Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580–584. Show EMT in CTCs that correlates with breast cancer treatment responses and relapse. Many of the mesenchymal CTCs circulated as multicellular clusters as compared to individual cells. This study clearly suggests the importance of EMT as a potential biomarker for therapeutic resistance and as a drug target in breast cancer
23. Dave B, Mittal V, Tan NM, Chang JC (2012) Epithelial–mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14:202
24. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751
25. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645–659
26. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA (2013) FOXC2 expression links epithelial–mesenchymal transition and stem cell properties in breast cancer. Cancer Res 73:1981–1992